Download MendeleyA new allosteric site in glycogen phosphorylase b as a target for drug interactions.
Oikonomakos, N.G., Skamnaki, V.T., Tsitsanou, K.E., Gavalas, N.G., Johnson, L.N.(2000) Structure 8: 575-584
- PubMed: 10873856
- DOI: https://doi.org/10.1016/s0969-2126(00)00144-1
- Primary Citation of Related Structures:
1C50 - PubMed Abstract:
In muscle and liver, glycogen concentrations are regulated by the coordinated activities of glycogen phosphorylase (GP) and glycogen synthase. GP exists in two forms: the dephosphorylated low-activity form GPb and the phosphorylated high-activity form GPa. In both forms, allosteric effectors can promote equilibrium between a less active T state and a more active R state. GP is a possible target for drugs that aim to prevent unwanted glycogen breakdown and to stimulate glycogen synthesis in non-insulin-dependent diabetes. As a result of a data bank search, 5-chloro-1H-indole-2-carboxylic acid (1-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethy l)amide, CP320626, was identified as a potent inhibitor of human liver GP. Structural studies have been carried out in order to establish the mechanism of this unusual inhibitor.
Organizational Affiliation:
Institute of Biological Research and Biotechnology, The National Hellenic Research Foundation, Athens, 11635, Greece. nikos@krokees. eie.gr.
